This striking finding paves the way to improve the therapeutic effect of AML or myelodysplastic syndromes (MDS) in combination with FTO inhibitors or anti-LILRB4 monoantibody based on HMAs. This evidence concerns the gene LILRB4 and acute myeloid leukemia.